Date: 2011-11-17
Type of information: R&D agreement
Compound:
Company: Cenix BioScience (Germany) SYGNIS Bioscience (Germany)
Therapeutic area: CNS diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: Cenix BioScience has signed a research agreement with SYGNIS Bioscience GmbH & Co. KG, a pharmaceutical company dedicated to developing innovative therapies for the treatment of disorders of the central nervous system.
Under the research agreement's first assignment to advance the SYGNIS KIBRA project, Cenix will apply its long-standing expertise in combining high content screening with gene silencing analyses in cultured human cells, to establish and optimize multi-parametric microscopy-based assays using the Definiens XD image analysis system. Using such assays, Cenix will conduct target validation to prioritize novel therapeutic drug target candidates, thereby accelerating and enriching the SYGNIS drug development pipeline.
Financial terms: Financial terms were not disclosed.
Latest news:
